The Blood Donor BIOBANK



Similar documents
Blood Biobanking Chances and Risks. The Bavarian Red Cross Blood Donor Biobank

Information for patients and the public and patient information about DNA / Biobanking across Europe

Biobank Alliance. H.-Erich Wichmann. English version. Helmholtz Zentrum München LMU München

PG Certificate / PG Diploma / MSc in Clinical Pharmacy

Biobanks: DNA and Research

PARTICIPANT INFORMATION

Secondary Use of the EHR via Pseudonymisation

CHAPTER 17: HEALTH PROMOTION AND DISEASE MANAGEMENT

Secondary Use of the EHR via Pseudonymisation

Roche Position on Human Stem Cells

Living benefits. Oasis. A look at critical illness insurance claims

Patient Centricity and the Changing Landscape of Healthcare

Medical Surgical Nursing (Elsevier)

Education Program Curriculum

Annette Pollex-Krüger, Johannes Drepper, Sebastian C. Semler. Telematikplattform für Medizinische Forschungsnetze (TMF) e.v.

Taking Part in Research at University Hospitals Birmingham

EDRN s Validation Study Information Management System

INFORMATION LEAFLET. If anything is not clear, or if you would like more information, please

TAKING PART IN CANCER TREATMENT RESEARCH STUDIES

CONSENT FOR MEDICAL TREATMENT

Business Loan Insurance Plan Critical Illness Claim - Policy 57903

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness

Personal Insurance. Do I need Trauma cover? a safety. to help get you back on track

NATIONAL HEALTH FUND PRESENTATION

EiCon G.m.b.H. Diagnostic Healthcare Consulting. Amtsgericht Lörrach : HRB-Nr info@eiconnet.de. Home page:

Vita 34 Parents Guide to umbilical Cord Blood Banking. secure first-class innovative

Genomics and Family History Survey Questions Updated March 2007 Compiled by the University of Washington Center for Genomics & Public Health

Group Benefits Evidence of Insurability for Comprehensive Optional Critical Illness Insurance

17th Eemeli Workshop. Wednesday 13th August 2014 VTT, Micronova, Tietotie 3, Espoo. Juhani Luotola, Orion Diagnostica Oy

How To Determine The Prevalence Of Microalbuminuria

Contact. Laboratory for Clinical Trials Laboratoire des Essays Cliniques Laboratorio de Ensayos Clinicos

Prognostic impact of uric acid in patients with stable coronary artery disease

COURSE APPROVAL GUIDELINES APS COLLEGE OF HEALTH PSYCHOLOGISTS

Member Health Management Programs

Physician and other health professional services

The M.U.R.D.O.C.K. Study

Regulatory Writing Clinical Project Management Strategic Communications

Big Data for Population Health

Date of birth Gender NHS number (if known) Town/Country of birth. Home Telephone no. Work Telephone no.

Male New Patient Package

MEDICAL-SURGICAL EYE CARE, P.A.

Personal Training Health Screening Questionnaire

CORPORATE WELLNESS PROGRAM

1MFBTF GJMM PVU GPSNT BOE GBY 'PSNT XJMM CF TJHOFE BU ZPVS BQQPJOUNFOU

STANDARD BLOOD PRODUCTS AND SERVICES

Big Data for Population Health and Personalised Medicine through EMR Linkages

Master of Science in Medical Writing Curriculum*

BIOBANK QUALITY. Office:

A Detailed Data Set From the Year 2011

Biomarkers for early detection of asbestosassociated

The 100,000 genomes project

Genetic Testing, Insurance Underwriting and Adverse Selection

Never Stand Stil Faculties of Science and Medicine

THE NHS HEALTH CHECK AND INSURANCE FREQUENTLY ASKED QUESTIONS

For customers Friends Life Individual Protection. Childcover benefit

Your Guide to Express Critical Illness Insurance Definitions

Evidence-Based Practice for Public Health Identified Knowledge Domains of Public Health

Group Critical Illness Insurance Provides lump-sum cash benefits that can help with daily expenses

Federal Ministry of Education and Research

Centre for Biomarker Research in Medicine. COMET Competence Centre for Excellent Technologies

A CONSUMER'S GUIDE TO CANCER INSURANCE. from YOUR North Carolina Department of Insurance CONSUMER'SGUIDE

Population Health Management Program

Leitfaden für die Antragstellung zur Förderung einer nationalen Biomaterialbankeninitiative

Non-covered ICD-10-CM Codes for All Lab NCDs

EPF Position Statement on the European Commission s proposal for a Regulation on In Vitro Medical Devices

Collaborative Onsite Medical Care in the Workplace

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012

Health Innovation. Innovation for health includes the. diagnostics and medical devices, as

Physician address. Physician phone

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment Chapter3 ValueandSpending...

FDA Considerations Regarding Frequent Plasma Collection Procedures

Life Insurance Application Form

TRACKS GENETIC EPIDEMIOLOGY

ECRIN (European Clinical Research Infrastructures Network)

Prostate Cancer Screening. A Decision Guide for African Americans

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Introducing. Accelerating employee engagement to drive healthier lifestyles

Primary Care Quality Care Indicators - Accuro EMR Prevention

How To Get A Medical Insurance Plan From A Doctor

Training Medical Technologists in the United States: Current State and Future Challenges

The MBBS/BSc programme of study is an integrated programme extending over 6 years.

Chapter 2: Health in Wales and the United Kingdom

Transcription:

The Blood Donor BIOBANK the first successful combination of blood donation and biobanking for medical research 1 1 Zoglmeier et al., TRANSFUSION 2011, 51(5): 1121-1122 Dr. Franz Weinauer SWISSTRANSFUSION 2011, Fribourg/CH

Outline Biobanking and blood donation Why the Bavarian Red Cross Blood Donor Service? Ethical and data protection issues Financing concepts Examples of research projects Successes and challenges

Why biobanking? Increased focus on personalised medicine, early diagnosis / / prevention in order to reduce costs of health care system Improved methods for biomarker analysis, high throughput assays/multiplexes Growing demand for biological samples obtained under standardised conditions for biomarker research High quality biobank may replace clinical study and save time and money

Value of biobanks The value of a biobank depends on: the number of samples and data the quality of sample processing/storage and data the IT infrastructure continuous investments long-term compliance of participants the design of biobank and study

Two types of biobanks Disease biobank Prospective biobank Zur Anzeige w ird der QuickTime Dekompressor TIFF (Unkomprimiert) benötigt. Zur Anzeige w ird der QuickTime Dekompressor TIFF (Unkomprimiert) benötigt. Zur Anzeige w ird der QuickTime Dekompressor TIFF (Unkomprimiert) benötigt. Zur Anzeige w ird der QuickTime Dekompressor TIFF (Unkomprimiert) benötigt. Zur Anzeige w ird der QuickTime Dekompressor TIFF (Unkomprimiert) benötigt. Enrollment, sample and data collection Enrollment, sample and data collection 5 year follow-up 10 year follow-up 15 year follow-up Monitor changes in life-style and health status

Prospective biobanks Pros: Covers many different diseases Large numbers of reliable controls Suitable for epidemiological studies Prospective, tailored data collection, life style monitoring Serial and pre-diagnostic samples from individual biobank participants Cons: Sufficient numbers of participants required Not predictable when and how many participants become ill High degree of compliance / long-term commitment required High infrastructure, administration and storage costs

Why a blood donor service? Existing infrastructure for: Large volume operation Sample and data storage Sample traceability Networking capability Large pool of blood donors Standards for the manufacture of pharmaceutical blood products: experienced, trained employees CLIA/GMP standards QM system (SOPs, audits,..)

Blood banks in Germany Red Cross blood banks are responsible for 80% of the German blood supply 8 blood banks collect 4,5 mio blood units of approximately 2 mio blood donors per year Legal requirement for a 5-year storage of plasma samples for backtracking since 1998 The Bavarian Red Cross (BRK) Blood Donor Service is the only Red Cross blood bank with a central production and storage facility

The BRK Blood Donor Service Pharmaceutical company founded in 1953 5 institutes for transfusion medicine and 1 central production and storage site 20 blood drive sessions a day, 5 days a week > 33,000 laboratory tests daily > 700 employees > 250 medical doctors > 18,000 honorary helpers 500,000 blood units p.a. collected from 400,000 blood donors Zur Anzeige wird der QuickTime Dekompressor BMP benötigt.

Central storage facility Sample storage at -42 C in one of the world s largest, fully automated biorepositories in Wiesentheid Built for storage of pharmaceutic plasma 2011: ~ 4 mio. samples stored (900,000 samples with informed consent) 2011: New -80 C storage facility for the long term-storage of selected samples implemented

Standardised and qualified processes All blood donations are uniformly processed and stored in the central production site in Wiesentheid Proven, highly standardised processes, as implemented for pharmaceutical production of blood products DIN EN ISO 9001certified quality management of all departments since 2008 Qualified personnel, years of experience

Large pool of blood donors

Representativity of blood donors Blood donors are representative of the general Bavarian population 1 Exceptions: smoking, asthma, heart attack 4500 4000 3500 3000 Zur Anzeige wird der QuickTime Dekompressor BMP benötigt. 2500 2000 1500 1000 500 0 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 Age distribution of blood donors weiblich männlich female male 1 The BSD health study: a pilot study to examine the comparability of Bavarian blood donors with the Bavarian general population by a comparison with KORA S4. Müller et al., Gesundheitswesen 2009; 71:481-8

Pre-diagnostic blood samples

Diseases covered in the Blood Donor BIOBANK approx. 4500 Blood Donor BIOBANK participants with diseases: cancer (prostate, breast, skin, gastrointestinal tract) cardiac diseases diabetes vascular diseases stroke CNS diseases autoimmune, gastrointestinal, respiratory diseases

Resources of the Blood Donor BIOBANK Serial, pre-diagnostic plasma samples for biomarker research, especially for slowly progressing / chronic diseases Data for epidemiologic studies Highly compliant donor pool for fast recruitment of study participants Established, powerful infrastructure for the conduction of prospective studies, screening and prevention campaigns

Ethical and legal issues Issues relating to all biobanks: Protection of personal data Information and informed consent of participants Purpose for sample use, quality of research Transfer of ownership Communication of study results Special issues of blood donation and biobanking: Separation of blood donation and biobank participation Potential damage of trust Extension of the medical scope of blood donation

Ethics vote Responsible national ethics committee: Ethics review board of the Bayerische Landesärztekammer Positive ethics vote allowing general informed consent Additional review of research projects to ensure proper use of samples and data

Informed consent Key documents: Participant information and informed consent form Documents are read and signed at home, no pressure to participate IC allows general use of samples and data for research Genetic analyses excluded Initial disease information by biobank participant For further (study-specific) medical data blood donors are re-contacted No individual communication of study results (German documents can be downloaded at www.biobank.de)

Data protection Data protection concept was established following guidelines for biobanks established by TMF 1 : Separation of personal and medical data! Practical implementation: personal and medical data stored in separate databases on separate servers pseudonymisation of data in research database (using 2 codes) access strictly limited to qualified, dedicated personnel supervision by internal data protection officer 1 Telematikplattform für Medizinische Forschungsnetze

Prerequisite for use of samples o.k. Backtracking tests (e.g. infection state) Other uses (e.g. research) Pseudonymisation Ethics vote Data protection Participants information Written informed consent

Financing concepts The Bavarian Red Cross Blood Donor Service is a not-forprofit organisation, but investments are required to ensure biobank quality and sustainability: Fee-for-service : BIOBANK provides samples and data for a customer Funding: collaboration projects between BIOBANK and research institutes / companies Licensing contracts

Donor rewarding Zur Anzeige wird der QuickTime Dekompressor TIFF (Unkomprimiert) benötigt. Zur Anzeige wird der QuickTime Dekompressor TIFF (Unkomprimiert) benötigt.

Projects Since 2006 about 20 research projects using Blood Donor BIOBANK samples have been performed Project partners: small and large pharmaceutical and diagnostic companies, academic research institutes Main indications: cancer, cardio- and cerebrovascular diseases, diabetes

Selected projects Colon cancer: identification of a panel of new, early biomarkers using mass spectrometry/multiplex assays Stroke: evaluation of the prognostic value of previously identified biomarkers Coronary disease: evaluation of the prognostic value of previously identified biomarkers

Diabetes screening studies Two studies were performed to screen blood donors for their risk to develop type 2 diabetes: 2005: 10.000 blood donors (recruited within 2 weeks) 2008: 61.000 blood donors (recruited within 2 months) Benefit for blood donors: early diagnosis, preventive measures Benefit for BIOBANK: increase number of biobank-participants, samples and data from early diabetic patients Participation rate: approx. 80%

Diabetes study 2008 Example of a combined epidemiological/diagnostic study Blood Donor Service: screening, providing samples and data Research companies: analysis of samples and data Academic institutes: scientific advice, data analysis

m 4 excellence cluster Blood Donor BIOBANK is part of the Munich excellence cluster m 4 - personalised medicine Funded by the BMBF (Bundesministerium für Bildung und Forschung) Aim of our project: Implementation of an additional -80 C storage facility for categorised long-term storage of selected samples; improvement of infrastructure; networking m 4 - Biobank alliance: posters No. 812 and 813

History 2001 2003 Preparatory phase BIOBANK 2006 Official launch BIOBANK 2,5 mio samples 2011 Approx. 4 mio samples 70.000 biobank participants 20 research projects New -80 C storage facility Start of sample collection

Achievements Several successful projects conducted Large screening studies performed within short time new biomarkers identified, proving sample quality m 4 funding allows improvement of infrastructure Growing demand for biobank samples observed

Remaining challenges Despite existing infrastructure major investments There is less money spent on diagnostic than on pharmaceutic development Limitation to plasma samples Identification of diseased blood donors Validation of medical data

Thank you for your attention!